New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
16:37 EDTWXWuXi PharmaTech narrows FY12 revenue view to $495M-$498M from $488M-$498M
FY12 consensus $496.85M. Sees FY12 operating margin of about 17.5% on a GAAP basis and about 20.5% on a non-GAAP basis, compared to previous guidance of 17%-18.0% and 20.0%-21.0%, respectively.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
05:21 EDTWXWuXi PharmaTech announces holders approval of merger agreement
WuXi PharmaTech announced that at an extraordinary general meeting of shareholders, the company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger dated as of August 14, and amended on October 20 and November 20, with New WuXi Life Science and WuXi Merger Limited, a wholly owned subsidiary of Parent, pursuant to which Merger Sub will be merged with and into the company with the company surviving as a wholly owned subsidiary of Parent, and to authorize and approve any and all transactions contemplated by the Merger Agreement, including the Merger. The parties currently expect to complete the Merger next month, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement. If and when completed, the Merger would result in the company becoming a privately held company, and its ADSs would no longer be listed on the New York Stock Exchange.
November 20, 2015
07:57 EDTWXWuXi PharmaTech to host special shareholder meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use